| Symbol | BICTF |
|---|---|
| Name | BIOCURE TECHNOLOGY INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V6E 2E9 Canada BC 300-1055 West Hastings Street |
| Telephone | 604-609-7146 |
| Fax | — |
| — | |
| Website | http://biocuretech.com |
| Incorporation | CA |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Dale Matheson Carr-Hilton Labonte LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | 0001831492 |
| Description | Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Additional info from OTC: |
Pink Current symbol attribute type Security_Name was changed. Previous value: -. New value: BIOCURE TECHNOLOGY INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: BIOCURE TECHNOLOGY INC.
Read more